Maxims latest update....
http://www.immutep.com/investors-me...partners-are-busy-novartis-gsk-eoc-china.html
Of interest Maxim's suggest GSK is moving into PH2 with IMP731 whereas as
the very recent operational update by immutep states it was simply building
on current PH1 in a different direction.....
I think I'm reading that correctly.......
If Maxims is correct, that means we will be associated with 5 ph2 trials
by years end with tacti-Mel possibly not too far behind......Not bad in
4 years....
Ann: TACTI-mel Patient Recruitment Complete & Operational Update, page-16
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.005(1.56%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.5¢ | 31.5¢ | $465.8K | 1.452M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 587491 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 18585 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
